<DOC>
	<DOCNO>NCT01682720</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , antiviral efficacy GS-7977 ribavirin ( RBV ) participant genotype 2 3 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Sofosbuvir Ribavirin Treatment-Naive Treatment-Experienced Subjects With Chronic Genotype 2 3 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Age &gt; 18 chronic genotype 2 3 HCV infection HCV RNA &gt; 10,000 IU/mL screen Subjects must treatment naive treatment experience Presence absence cirrhosis ; liver biopsy may require Healthy accord medical history physical examination exception HCV diagnosis Agree use two form highly effective contraception duration study 6 month last dose study medication Prior use inhibitor HCV NS5B Polymerase History clinically significant chronic liver disease Evidence history decompensated liver disease HIV chronic hepatitis B virus ( HBV ) infection Hepatocellular carcinoma ( HCC ) malignancy ( exception certain resolve skin cancer ) Chronic use immunosuppressive agent immunomodulatory agent History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study best interest subject opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>HCV</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
</DOC>